Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Rong Zhou Sells 7,000 Shares

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Rong Zhou sold 7,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $44.42, for a total transaction of $310,940.00. Following the completion of the transaction, the executive vice president now directly owns 118,469 shares of the company’s stock, valued at approximately $5,262,392.98. The trade was a 5.58 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Rong Zhou also recently made the following trade(s):

• On Tuesday, November 12th, Rong Zhou sold 6,893 shares of Amphastar Pharmaceuticals stock. The stock was sold at an average price of $48.88, for a total value of $336,929.84.

Amphastar Pharmaceuticals Trading Down 3.3 %

Amphastar Pharmaceuticals stock traded down $1.40 during midday trading on Monday, reaching $40.84. The stock had a trading volume of 597,259 shares, compared to its average volume of 402,867. The company has a fifty day moving average of $47.14 and a 200 day moving average of $44.65. Amphastar Pharmaceuticals, Inc. has a 52-week low of $36.56 and a 52-week high of $65.92. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The firm has a market cap of $1.96 billion, a price-to-earnings ratio of 13.61, a price-to-earnings-growth ratio of 0.87 and a beta of 0.78.

Analyst Ratings Changes

Several research firms recently weighed in on AMPH. StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Wells Fargo & Company assumed coverage on Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price objective for the company. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, Amphastar Pharmaceuticals has a consensus rating of “Hold” and an average price target of $60.33.

Institutional Trading of Amphastar Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the business. Assenagon Asset Management S.A. lifted its holdings in Amphastar Pharmaceuticals by 22.9% during the 2nd quarter. Assenagon Asset Management S.A. now owns 189,605 shares of the company’s stock valued at $7,584,000 after buying an additional 35,306 shares in the last quarter. Blue Trust Inc. boosted its stake in Amphastar Pharmaceuticals by 23.9% in the second quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock valued at $70,000 after acquiring an additional 309 shares in the last quarter. Raymond James & Associates increased its position in shares of Amphastar Pharmaceuticals by 16.9% during the second quarter. Raymond James & Associates now owns 114,719 shares of the company’s stock worth $4,589,000 after purchasing an additional 16,574 shares in the last quarter. 1620 Investment Advisors Inc. acquired a new position in shares of Amphastar Pharmaceuticals during the second quarter worth $93,000. Finally, Louisiana State Employees Retirement System lifted its holdings in shares of Amphastar Pharmaceuticals by 3.8% during the 2nd quarter. Louisiana State Employees Retirement System now owns 19,200 shares of the company’s stock valued at $768,000 after purchasing an additional 700 shares during the last quarter. 65.09% of the stock is currently owned by institutional investors.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.